Middle East And Africa Mass Spectrometry Market
市场规模（十亿美元）
CAGR :
% 
USD
2.81 Billion
USD
5.32 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 2.81 Billion |
 Market Size (Forecast Year) |
USD 5.32 Billion |
 CAGR |
% |
| Major Markets Players |
|
中東和非洲質譜市場細分，按技術（混合質譜、單質譜等）、模式（台式和獨立式）、應用（生命科學研究、藥物發現、環境測試、食品檢測、應用行業、臨床診斷等）、最終用戶（製藥業、研究和學術機構、食品飲料業、石化業等）、分銷渠道（直接投標、零售等）——行業趨勢和預測到 2032 年
中東和非洲質譜市場規模
- 2024 年中東和非洲質譜市場規模為28.1 億美元 ，預計 到 2032 年將達到 53.2 億美元，預測期內 複合年增長率為 8.30%。
- 市場成長主要得益於製藥、生物技術和環境測試領域對先進診斷工具和分析儀器日益增長的需求，特別是隨著該地區醫療保健和研究基礎設施的不斷發展
- 此外，慢性病發病率的上升、政府對科研的支持力度的加大以及高通量技術的日益普及，正在推動質譜技術在臨床和科研應用中的整合。這些因素正在加速質譜解決方案的普及，從而顯著促進行業成長。
中東和非洲質譜市場分析
- 質譜法是一種用於識別和量化化學化合物的強大分析技術，由於其高靈敏度、準確性和分析複雜混合物的能力，在中東和非洲的製藥、環境檢測、食品安全和臨床診斷等領域的應用越來越重要。
- 質譜分析需求的不斷增長主要源於醫療保健和研究領域的擴大、慢性病和傳染病發病率的上升以及對藥品安全和環境監測的監管力度不斷加大
- 沙烏地阿拉伯在中東和非洲質譜市場佔據主導地位，2024 年其收入份額最大，為 35.1%，這得益於政府對醫療基礎設施、藥物研究以及透過國家衛生和科學計畫建立現代化實驗室的大力投資
- 由於研究活動、學術合作以及對先進診斷工具的需求不斷增長，預計南非將成為預測期內中東和非洲質譜市場成長最快的國家
- 混合質譜技術在中東和非洲質譜市場佔據主導地位，2024 年的市場份額為 41.7%，這得益於其卓越的分析性能以及在海灣合作委員會國家和南非的臨床診斷、蛋白質組學和藥物發現應用中的廣泛應用
報告範圍和中東和非洲質譜市場細分
|
屬性 |
中東和非洲質譜關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
中東和非洲
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
中東和非洲質譜市場趨勢
“質譜技術在臨床和環境應用中的日益融合”
- 中東和非洲質譜市場的一個重要且加速的趨勢是，這種分析技術在臨床診斷和環境檢測領域的整合不斷擴大，這是由日益增長的公共衛生問題、日益加強的污染監測以及對精準醫療日益重視所推動的。
- 例如，沙烏地阿拉伯和阿聯酋的醫療機構越來越多地採用液相層析串聯質譜法 (LC-MS/MS) 等質譜技術來早期檢測代謝疾病和傳染病，因為它們比傳統診斷工具具有更高的特異性和靈敏度
- 該地區的環境機構，尤其是南非，正在利用質譜技術監測空氣和水質，檢測重金屬，並確保符合不斷發展的環境標準。政府支持的研究計畫進一步鼓勵在實驗室和大學部署先進的分析系統。
- 該技術在食品安全檢測和法醫學領域的應用也日益廣泛，公共和私人實驗室紛紛投資混合和高分辨率質譜儀進行複雜化合物分析
- 跨行業應用的興起正在重塑區域需求格局，鼓勵供應商推出更多針對特定應用、結構緊湊且用戶友好的質譜系統。賽默飛世爾科技和安捷倫科技等公司正在透過合作夥伴關係和分銷商網絡擴大其業務，以滿足日益增長的需求。
- 法規遵循、準確診斷和即時分析的重要性日益增加，推動了質譜技術融入關鍵領域，鞏固了其作為區域科學和工業發展基石技術的地位
中東和非洲質譜市場動態
司機
“臨床診斷和藥物研究的需求不斷增長”
- 臨床診斷和藥物開發對準確、快速、靈敏的分析工具的需求日益增長，這是中東和非洲質譜市場的主要驅動力
- 例如，2024 年，沙烏地阿拉伯和阿聯酋的多家醫院和診斷中心透過投資 LC-MS/MS 和混合質譜系統來擴展其能力，用於對疾病生物標記進行高通量分析和治療藥物監測
- 隨著該地區各國政府增加醫療保健支出和對生物醫學研究的支持，各機構正在優先考慮質譜分析，因為它能夠提供對標靶治療和疫苗開發至關重要的精確分子洞察
- 此外，埃及和南非等國的製藥業正在轉向質譜法進行品質控制、代謝組學和化合物表徵，從而推動了持續的設備需求
- 個人化醫療的推動，加上臨床實驗室和學術研究中心的擴張，進一步加速了質譜技術在整個地區醫療保健和生命科學應用中的整合
克制/挑戰
“成本高，技術要求高”
- 中東和非洲質譜市場面臨的主要挑戰之一是儀器的初始成本高，以及需要專門的技術知識來操作和解釋結果
- 例如，先進的混合質譜系統可能需要大量的資本投資，這可能會限制預算有限的小型實驗室或研究中心的採用
- 此外，質譜設備的操作需要熟練的人員進行樣品製備、儀器校準和數據分析，這在缺乏訓練有素的分析化學家或實驗室科學家的地區可能是一個障礙
- 雖然供應商正在努力推出更自動化和用戶友好的系統，但質譜技術複雜性仍然限制著其更廣泛的普及，特別是在資源匱乏的環境或農村地區
- 應對這項挑戰需要在勞動力培訓、透過學術合作進行能力建設以及針對該地區特定應用需求提供具有成本效益的解決方案方面進行協調努力
中東和非洲質譜市場範圍
市場根據技術、模式、應用、最終用戶和分銷管道進行細分。
- 依技術
根據技術，中東和非洲質譜市場細分為混合質譜、單一質譜和其他技術。混合質譜技術佔據市場主導地位，2024 年收入份額最高，達到 41.7%，這得益於其在複雜樣品分析中更高的靈敏度、分辨率和準確度。混合質譜技術在蛋白質體學、代謝組學和藥物動力學研究中的卓越性能，使其對沙烏地阿拉伯和南非等國的研究和臨床實驗室具有極高的價值。對精準診斷和先進分析技術日益增長的需求，持續推動該地區混合質譜系統的採用。
預計單質譜分析領域將在2025年至2032年間實現最快成長，這得益於其價格實惠，且適用於食品檢測、石化和學術應用的常規分析。許多小型實驗室和機構更傾向於使用單質譜系統進行基本的定量和定性分析，因為其操作複雜性較低且成本效益較高。
- 按方式
根據使用模式，中東和非洲質譜市場分為桌上型和獨立式。台式質譜在2024年佔據了最大的市場份額，佔據了最大的市場份額，這歸因於其在臨床和製藥實驗室的研究、藥物研發和品質控制應用中的廣泛使用。桌上型系統靈活性高，且易於與色譜系統集成，使其成為高性能分析環境的首選。
預計獨立細分市場將在 2025 年至 2032 年間見證最快的複合年增長率，這得益於其便攜性以及在環境監測、法醫調查和現場應用中的現場測試的適用性，尤其是在偏遠或服務不足的地區。
- 按應用
根據應用，市場細分為生命科學研究、藥物研發、環境檢測、食品檢測、應用產業、臨床診斷等。臨床診斷領域佔據主導地位，在2024年佔據最大的市場收入份額，這得益於質譜技術在生物標記分析、代謝篩檢和傳染病檢測中的應用日益增多，尤其是在沙烏地阿拉伯和南非的醫院和診斷中心。
預計環境檢測領域將在 2025 年至 2032 年間實現最快的成長率，這得益於該地區環保意識的提高以及政府對污染控制和水質評估的監管。
- 按最終用戶
根據最終用戶，中東和非洲質譜市場細分為製藥業、科研和學術機構、食品飲料產業、石化產業及其他產業。由於質譜在藥物開發、驗證和品質保證過程中發揮關鍵作用，製藥業在2024年佔據了最大的市場份額，佔據了市場主導地位。沙烏地阿拉伯和埃及製藥商的大量投資也推動了質譜市場的需求。
在政府資金不斷增加、國際合作以及整個地區大學實驗室基礎設施不斷擴大的支持下，研究和學術機構領域預計將在 2025 年至 2032 年間見證最快的增長。
- 按分銷管道
根據分銷管道，中東和非洲質譜市場細分為直接招標、零售和其他。 2024年，直接招標市場佔據了最大的市場收入份額，這主要得益於醫院、公共實驗室和政府資助機構透過集中採購系統進行批量設備採購，尤其是在海灣合作委員會地區。
由於透過專業經銷商和線上平台提供的質譜系統越來越多，滿足了城市地區小型實驗室和私人診所的需求，預計零售部門將在 2025 年至 2032 年間見證最快的複合年增長率。
中東和非洲質譜市場區域分析
- 沙烏地阿拉伯在中東和非洲質譜市場佔據主導地位，2024 年其收入份額最大，為 35.1%，這得益於政府對醫療基礎設施、藥物研究以及透過國家衛生和科學計畫建立現代化實驗室的大力投資
- 國家對推動醫學診斷和科學研究的重視，導致醫院、研究機構和環境機構越來越多地部署先進的質譜系統
- 國家衛生戰略、精準醫療需求的不斷增長以及與全球分析儀器製造商的合作進一步支持了這一增長，使質譜技術成為公共和私營部門的關鍵技術
沙烏地阿拉伯質譜市場洞察
2024年，沙烏地阿拉伯質譜市場佔據了中東和非洲地區最大的收入份額，這得益於國家醫療轉型計畫和對科學研究的大力投入。沙烏地阿拉伯對生物技術、醫藥創新和臨床診斷的重視，促使領先的醫院和研究中心紛紛安裝混合色譜和液質聯用系統。沙烏地阿拉伯致力於成為區域醫療保健和研究中心，並將繼續在高端分析技術的應用方面保持領先地位。
南非質譜市場洞察
受環境檢測、食品品質保證和學術研究需求不斷增長的推動，南非質譜市場預計將在預測期內實現顯著的複合年增長率。政府旨在提升實驗室能力並加強採礦、農業和製藥等行業監管審查的舉措正在推動需求成長。此外，大學和研究機構在拓展質譜在蛋白質體學和疾病生物標記研究中的應用方面發揮關鍵作用。
阿聯酋質譜市場洞察
受診斷技術進步和生命科學領域創新的大力支持推動，阿聯酋質譜市場預計將穩步擴張。阿聯酋在醫療旅遊、科研合作和實驗室自動化方面的投資，正推動公共和私營部門對質譜技術的採用。對便攜式和用戶友好系統的需求也在增長，尤其是在臨床診斷和食品安全應用領域，這與阿聯酋對健康安全和永續發展的重視相一致。
中東和非洲質譜市場份額
中東和非洲質譜產業主要由知名公司主導，其中包括：
- 賽默飛世爾科技公司（美國）
- 安捷倫科技公司（美國）
- 沃特世公司（美國）
- 布魯克公司（美國）
- 島津製作所（日本）
- 珀金埃爾默（美國）
- JEOL株式會社（日本）
- LECO公司（美國）
- 耶拿分析儀器有限公司（德國）
- 日立高科技公司（日本）
- 丹納赫公司（美國）
- MKS Instruments, Inc.（美國）
- Biotage AB（瑞典）
- Advion, Inc.（美國）
- KNAUER Wissenschaftliche Geräte GmbH（德國）
- Hiden Analytical Ltd.（英國）
- MassTech, Inc.（美國）
- Isotopx有限公司（英國）
- Markes International Ltd.（英國）
中東和非洲質譜市場的最新發展是什麼？
- 2024年5月，賽默飛世爾科技公司宣布將透過設立區域培訓和應用支援中心，擴大在阿拉伯聯合大公國的業務。該中心旨在提升中東地區先進分析儀器（包括質譜系統）的採用率和運作效率。該計劃彰顯了賽默飛世爾致力於提供本地化技術支持，並促進該地區實驗室專業人員技能發展的承諾。
- 2024年4月，安捷倫科技公司與沙烏地阿拉伯阿卜杜拉國王科技大學 (KAUST) 合作，利用最先進的混合質譜平台支持其正在進行的代謝組學和蛋白質組學研究。此次合作旨在增強沙烏地阿拉伯在分子診斷和藥物研發方面的科研能力，協助實現「沙烏地阿拉伯2030願景」下建立知識型經濟的宏偉目標。
- 2024年3月，沃特世公司與南非當地大學和醫療機構合作，在南非啟動了一項行動質譜推廣計畫。該計劃旨在提高學生、研究人員和醫療資源匱乏地區的診斷實驗室對高解析度質譜技術的認知、教育和可及性。該計劃體現了沃特世對新興市場分析科學能力建設和發展的重視。
- 2024年2月，布魯克公司宣佈在開羅美國大學安裝其timsTOF Pro 2質譜儀，標誌著埃及蛋白質體學研究能力的顯著提升。該系統將用於先進的生物醫學和製藥研究，促進高通量分析和生物標記發現。此舉彰顯了布魯克致力於透過創新儀器支持非洲生命科學研究的決心。
- 2024年1月，島津公司擴大了在中東地區的經銷商網絡，以增強其質譜產品線的區域覆蓋和售後支援。這項策略性措施旨在滿足臨床診斷、食品安全檢測和環境監測領域日益增長的需求。島津對區域基礎設施的投資彰顯了其致力於在中東和非洲地區提昇科研水準和市場影響力的決心。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PIPELINE ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING PREVALENCE OF CANCER AND OTHER TARGET DISEASES
5.1.2 GROWING AWARENESS AND ACCEPTANCE OF CAR-T CELL THERAPY
5.1.3 SUPPORTIVE GOVERNMENT INITIATIVES AND FUNDING FOR HEALTHCARE INNOVATION
5.2 RESTRAINTS
5.2.1 HIGH COST OF CAR-T CELL THERAPY
5.2.2 REGULATORY HURDLES RESULT THE DELAY IN CAR T-CELL THERAPY APPROVAL
5.3 OPPORTUNITIES
5.3.1 THE EXTENSIVE PIPELINE OF CAR-T CELL THERAPY
5.3.2 THE DEVELOPMENT OF NOVEL THERAPIES AND COMBINATION TREATMENTS
5.4 CHALLENGES
5.4.1 POTENTIAL RISKS AND ADVERSE EFFECTS OF TREATMENT
5.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS AND THERAPIES
6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENTN MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 AUTOLOGOUS CAR-T CELLS
6.3 ALLOGENEIC CAR-T CELLS
7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY STRUCTURE
7.1 OVERVIEW
7.2 SECOND GENERATION CAR-T CELLS
7.3 THIRD GENERATION CAR-T CELLS
7.4 FOURTH GENERATION CAR-T CELLS
7.5 FIRST GENERATION CAR-T CELLS
8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN
8.1 OVERVIEW
8.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES
8.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19)
8.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30)
8.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22)
8.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20)
8.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33)
8.3 ANTIGENS ON SOLID TUMORS
8.4 OTHERS
9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY BRAND
9.1 OVERVIEW
9.2 KYMRIAH
9.3 YESCARTA
9.4 TECARTUS
9.5 OTHERS
10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY THERAPEUTICS APPLICATION
10.1 OVERVIEW
10.2 DIFFUSE LARGE B-CELL LYMPHOMA
10.3 FOLLICULAR LYMPHOMA
10.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
10.5 MANTLE CELL LYMPHOMA
10.6 MULTIPLE MYELOMA
10.7 LUNG CANCER
10.8 CHRONIC LYMPHOCYTIC LEUKEMIA
10.9 GASTRIC CANCER
10.1 PANCREATIC CANCER
10.11 BREAST CANCER
10.12 OTHERS
11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 OTHERS
12 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY MARKET BY, DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 HOSPITAL PHARMACY
12.3 OTHERS
13 MEA, SAUDI ARABIA, SEA CAR-T CELL THERAPY MARKET, BY COUNTRY
13.1 MEA
13.1.1 SAUDI ARABIA
13.1.2 U.A.E.
13.1.3 SOUTH AFRICA
13.1.4 ISRAEL
13.1.5 KUWAIT
13.1.6 EGYPT
13.1.7 REST OF MIDDLE EAST & AFRICA
13.2 SEA
13.2.1 SINGAPORE
13.2.2 MALAYSIA
13.2.3 THAILAND
13.2.4 INDONESIA
13.2.5 PHILIPPINES
13.2.6 VIETNAM
14 MEA AND SEA CAR-T CELL THERAPY MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MEA
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 NOVARTIS AG
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 GILEAD SCIENCES, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 BRISTOL-MYERS SQUIBB COMPANY
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 JOHNSON & JOHNSON SERVICES, INC.
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表格列表
TABLE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 TOTAL STATISTICS OF PREVELENCE RATE OF CANCER -2022(KENYA)
TABLE 3 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 4 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 5 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)
TABLE 6 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE, 2022-2031 (USD MILLION)
TABLE 7 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)
TABLE 8 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGET ANTIGEN, 2022-2031 (USD MILLION)
TABLE 9 SEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 10 MEA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 11 SEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 12 MEA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 13 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 14 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 15 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)
TABLE 16 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTICS APPLICATION, 2022-2031 (USD MILLION)
TABLE 17 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 18 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 19 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 20 MEA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 23 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 24 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 25 SAUDI ARABIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 26 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 27 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 28 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 29 SAUDI ARABIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 30 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 31 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 32 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 33 U.A.E. ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 34 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 35 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 36 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 U.A.E. CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 38 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 39 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 40 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 41 SOUTH AFRICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 42 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 43 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 44 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 45 SOUTH AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 47 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 48 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 49 ISRAEL ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 50 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 51 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 52 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 53 ISRAEL CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 54 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 55 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 56 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 57 KUWAIT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 58 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 59 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 60 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 61 KUWAIT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 62 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 63 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 64 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 65 EGYPT ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 66 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 67 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 68 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 69 EGYPT CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 70 REST OF MIDDLE EAST & AFRICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 SEA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 72 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 73 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 74 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 75 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 78 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 80 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 81 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 82 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 83 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 84 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 85 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 86 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 87 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 88 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 89 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 90 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 91 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 92 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 93 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 94 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 96 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 97 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 98 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 99 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 100 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 101 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 102 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 103 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 104 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 105 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 106 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 107 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 108 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 109 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 110 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 112 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 113 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2022-2031 (USD MILLION)
TABLE 114 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 115 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2022-2031 (USD MILLION)
TABLE 116 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2022-2031 (USD MILLION)
TABLE 117 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2031 (USD MILLION)
TABLE 118 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
图片列表
FIGURE 1 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 2 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 8 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 10 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE MEA, SAUDI ARABIA AND SEA CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DIALYSIS MACHINES AND CONSUMABLES MARKET
FIGURE 14 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031
FIGURE 15 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 16 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 17 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2031
FIGURE 18 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2027-2031)
FIGURE 19 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031
FIGURE 21 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2024-2031)
FIGURE 22 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 23 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2031
FIGURE 24 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2027-2031)
FIGURE 25 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 26 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031
FIGURE 27 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, CAGR (2024-2031)
FIGURE 28 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, LIFELINE CURVE
FIGURE 29 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY TARGET ANTIGEN, 2031
FIGURE 30 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, CAGR (2027-2031)
FIGURE 31 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGET ANTIGEN, LIFELINE CURVE
FIGURE 32 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031
FIGURE 33 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2024-2031)
FIGURE 34 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE
FIGURE 35 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2031
FIGURE 36 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, CAGR (2027-2031)
FIGURE 37 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY BRAND, LIFELINE CURVE
FIGURE 38 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031
FIGURE 39 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, CAGR (2024-2031)
FIGURE 40 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE
FIGURE 41 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTICS APPLICATION, 2031
FIGURE 42 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, CAGR (2027-2031)
FIGURE 43 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY THERAPEUTICS APPLICATION, LIFELINE CURVE
FIGURE 44 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031
FIGURE 45 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2024-2031)
FIGURE 46 SEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, 2031
FIGURE 48 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, CAGR (2027-2031)
FIGURE 49 MEA CAR-T CELL THERAPY TREATMENTMARKET: BY END USER, LIFELINE CURVE
FIGURE 50 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031
FIGURE 51 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 52 SEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2031
FIGURE 54 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2027-2031)
FIGURE 55 MEA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 MEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)
FIGURE 57 SEA, CAR-T CELL THERAPY MARKET: SNAPSHOT (2023)
FIGURE 58 MEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 59 SEA CAR-T CELL THERAPY MARKET: COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
